

Title: Executive Summary of the Guidelines for the use of Interferon- γ Release Assays in the Diagnosis of Tuberculosis Infection.

Título: Sumario Ejecutivo de la Guía de Práctica Clínica sobre el uso de las pruebas de liberación de interferón- γ (IGRA) para el diagnóstico de Infección Tuberculosa

Authors: Panel of experts from the Mycobacteria Study Group (GEIM) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Respiratory Diseases and Thoracic Surgery (SEPAR)¹

Coordinators:

Miguel Santin

Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL; Department of Clinical Sciences, University of Barcelona; Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Phone number: 93 260 7625; mail address: msantin@bellvitgehospital.cat

José-María García-García

Clinical Unit of Pneumology; Hospital San Agustín; C/Camino de Heros, 4, 33400, Avilés, Asturias, Spain.

Phone number: 985 123 000 (Ext.: 24386, 23089); mail address: josemariagarciag@hotmail.com

José Domínguez

Service of Microbiology; Research Institute Trias i Pujol; Hospital Gremans Trias i Pujol, Carretera del Canyet, s/n, 08916 Badalona, Barcelona, Spain; Department of Genetics and Microbiology; Universidad Autónoma de Barcelona; CIBER Respiratory Diseases; Badalona, Barcelona, Spain.

Phone number: 934 978 977; mail address: jadomb@gmail.com

¹Writing Committee:

1. Miguel Santin. Service of Infectious Diseases; Bellvitge University Hospital-IDIBELL, C/Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona; Department of Clinical Sciences, University of Barcelona, Barcelona. Phone number: 93 260 76 25; mail address: msantin@bellvitgehospital.cat.

2. José-María García-García. Clinical Unit of Pneumology; Hospital San Agustín; C/Camino de Heros, 4, 33400, Avilés, Asturias, Spain.

Phone number: 985 123 000 (Ext.: 24386, 23089); mail address: josemariagarciag@hotmail.com

3. David Rigau. Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau), C/Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain. Phone number: 935 537 814; DRigau@santpau.cat.

4. Neus Altet. Unit of Tuberculosis Valle de Hebron; Institute of Research in Primary Assistance Jordi Gol; Unidad Clínica de Tratamiento Directamente Observado "Servicios Clínicos", C/García Mariño, 4, 08022, Barcelona. Phone number: 609 101 638; mail address: mneusagomez@gmail.com.

5. Luis Anibarro. Unit of Tuberculosis, Infectious Diseases, Service of Internal Medicine, Complejo Hospitalario de Pontevedra, 36001, Pontevedra, Spain. Phone number: 986 807 005; mail address: luis.anibarro.garcia@sergas.es.

6. Irma Casas. Service of Preventive Medicine, Hospital Germans Trias i Pujol, Carretera del Canyet, s/n, 08916 Badalona, Barcelona, Spain; Department of Pediatrics, Obstetrics-Gynecology and Preventive Medicine, Universidad Autónoma de Barcelona, Barcelona. Phone number: 934 978 977; mail address: icasas.germanstrias@gencat.cat.

7. Nuria Díez. Service of Pediatrics, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012, Valladolid, Spain. Phone number: 983 420 400 (Ext.: 85160); mail address: nuriadiez@hotmail.com.

8. Mercedes García-Gasalla. Service of Internal Medicine/Infectious Diseases, Hospital Son Llàtzer, Carretera de Manacor, 4, 07198, Palma de Mallorca, Spain. Phone number: 871 202 000; mail address: mercedesggasalla@yahoo.es.

9. Xavier Martínez-Lacasa. Unit of Tuberculosis Control, Hospital Universitario Mutua de Terrassa, Pza. Dr Robert, 5, 08224, Terrassa, Barcelona. Phone number: 937 365 050; mail address: smartinez@mutuaterrassa.cat.

10. Antón Penas. Unit of Tuberculosis, Service of Pneumology, Hospital Universitario Lucus Augusti, C/San Cibrao, 27003, Lugo. Phone number: 982 295 129; mail address: Anton.Penas.Truque@sergas.es.

11. Elvira Pérez-Escolano. Service of Internal Medicine, Infectious Diseases, Hospital de Jerez, Ctra. Circunvalación, s/n, 11407, Jerez de la Frontera, Cádiz, Spain. Phone number: 659 859 321; mail address: elvira.perez.escolano.sspa@juntadeandalucia.es.

12. Francisca Sánchez. Service of Infectious Diseases, Instituto Mar de Investigaciones Médicas (IMIM), Hospital del Mar; Dr. Aiguader, 88, 08003 Barcelona, Spain. Phone number: 932 483 251; mail address: FSanchezMartinez@parcdesalutmar.cat.

13. José Domínguez. Service of Microbiology, Institut d'Investigació Germans Trias i Pujol, Hospital Gremans Trias i Pujol; Department de Genètica I Microbiologia, Universitat Autònoma de Barcelona; CIBER Enfermedades Respiratorias; Carretera del Canyet, s/n, 08916 Badalona, Barcelona, Spain; Phone number: 934 978 977; mail address: jadomb@gmail.com

Correspondence:

José Domínguez

Service of Microbiology, Instituto de Investigación Trias i Pujol; Hospital Germans Trias i Pujol, Carretera del Canyet, s/n, 08916 Badalona, Barcelona, Spain; Departamento de Genética y Microbiología, Universidad Autónoma de Barcelona; CIBER Enfermedades Respiratorias; Badalona, Barcelona, Spain. Phone number: 934 978 977; mail address: jadomb@gmail.com.

Word count (summary):

Word count (manuscript):

References:

Tables:

Acknowledgements

External reviewers: Fernando Alcaide (Service of Microbiology, Bellvitge University Hospital, University of Barcelona, L'Hospitalet de Llobregat, Barcelona), Ángel Domínguez (Service of Infectious Diseases, Hospital Virgen Macarena, Sevilla), Jordi Dorca (Service of Pneumology, Bellvitge University Hospital, University of Barcelona, L'Hospitalet de Llobregat, Barcelona), María J. Mellado Peña (Service of General Pediatrics and Infectious and Tropical Diseases, Hospital Universitario Infantil La Paz, Madrid), Juan J. Palacios (Regional Laboratory for Mycobacteria, Hospital Universitario Central de Asturias, Oviedo, Asturias), Antonio Rivero (Service of Infectious Diseases, Hospital Reina Sofía, Córdoba), Anna Rodés (Program of Prevention and Control of Tuberculosis, Public Health Agency of Catalonia), Juan Ruíz Manzano (Service of Pneumology, Hospital Germans Trias i Pujol, Badalona, Barcelona).

The working group thanks SEPAR for providing the venue and infrastructure for the panel's meetings.

Funding and editorial independence

The panel received no funding from any for-profit companies or organizations. The Spanish Society of Respiratory Diseases and Thoracic Surgery (SEPAR) hosted the in-person meetings, while SEPAR and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) funded the travel and housing costs for members to attend the meetings. Neither the SEIMC nor SEPAR have direct or indirect influence on the elaboration of the guidelines.

Abstract

Introduction. Interferon-gamma release assays are widely used for the diagnosis of tuberculosis infection in low-prevalence countries. However, there is no consensus on their application. The objective of this study was to develop guidelines for the use of interferon-gamma release assays in specific clinical scenarios in Spain.

Methods. A panel of experts comprising specialists in infectious diseases, respiratory diseases, microbiology, pediatrics and preventive medicine, together with a methodologist, formulated the clinical questions and outcomes of interest. They conducted a systematic literature search, summarized the evidence and rated its quality, and prepared the recommendations following the GRADE (*Grading of Recommendations of Assessment Development and Evaluations*) methodology.

Results. The panel prepared recommendations on the use of interferon-gamma release assays for the diagnosis of tuberculosis infection in the contact-tracing study (both adults and children), health care workers, immunosuppressed patients (patients infected with human immunodeficiency virus, patients with chronic immunomediated inflammatory diseases due to start biological therapy and patients requiring organ transplant) and for the diagnosis of active tuberculosis. Most recommendations were weak, mainly due to the lack of good quality evidence to balance the clinical benefits and disadvantages of the interferon-gamma release assays as compared with the tuberculin skin test.

Conclusion. This document provides evidence-based guidance on the use of interferon-gamma release assays for the diagnosis of tuberculosis infection in patients at risk of tuberculosis or with suspicion of active disease. The guidelines will be applicable in specialist and primary care and in public health settings.

Resumen

Introducción. Las técnicas de detección in vitro de interferón-gamma (IGRA, del inglés interferon-gamma release assays), están ampliamente implantadas para el diagnóstico de infección tuberculosa en países de baja prevalencia. Sin embargo, no hay consenso sobre su aplicación. El objetivo fue desarrollar una guía de práctica clínica para el uso de los IGRA en los diferentes escenarios clínicos en España.

Métodos. Un grupo de expertos compuesto por especialistas en enfermedades infecciosas, enfermedades respiratorias, microbiología, pediatría y medicina preventiva, junto con un

metodólogo formularon las preguntas clínicas y los desenlaces de interés, llevaron a cabo una búsqueda sistemática de la literatura, sintetizaron la evidencia y graduaron su calidad, y formularon las recomendaciones siguiendo la metodología GRADE (*Grading of Recommendations of Assessment Development and Evaluations*).

Resultados. El grupo de trabajo formuló las recomendaciones sobre el uso de los IGRA para el diagnóstico de infección tuberculosa en el estudio de contactos (adultos y niños), trabajadores sanitarios, pacientes inmunosuprimidos (pacientes infectados por el virus de la inmunodeficiencia humana, pacientes afectos de enfermedades inflamatorias inmuno-mediadas candidatos a terapias biológicas y pacientes que requieren trasplante de órganos), y en el diagnóstico de enfermedad tuberculosa activa. La mayor parte de las recomendaciones fueron débiles, principalmente debido a la falta de evidencia de calidad para establecer un balance entre beneficios y daños de los IGRA en comparación con la prueba de la tuberculina.

Conclusión. Este documento proporciona una guía basada en la evidencia para el uso de los IGRA para el diagnóstico de infección tuberculosa en pacientes en riesgo de tuberculosis o con sospecha de enfermedad activa. Esta guía es aplicable en la atención especializada y primaria, y salud pública.

INTRODUCTION

The diagnosis of tuberculosis (TB) infection relied solely on the tuberculin skin test (TST) until a decade or so ago when *in vitro* immunodiagnostic tests, known as interferon-gamma release assays (IGRAs), became available. At present, the question of whether IGRAs should be used to complement or substitute the TST is under debate.

The aim of detecting TB infection is to identify and treat people at risk of developing active disease. Close-contacts of patients with TB, people infected with the human immunodeficiency virus (HIV), patients receiving immunosuppressive therapies, and health care workers are all at risk of active TB. Therefore, screening and preventive chemotherapy in cases of infection should be considered in these populations (1). The TST consists of the intradermal injection of PPD-S (Seibert's purified protein derivative), or the PPD-RT23 equivalent in Spain. However, this contains a mixture of more than 200 antigens that are shared by mycobacteria other than *Mycobacterium tuberculosis*, and includes the vaccine strain of *Mycobacterium bovis* bacillus Calmette-Guérin (BCG). Therefore, people sensitized by previous exposure to non-tuberculous mycobacteria (NTM) or the BCG vaccine may respond to a TST. Another major limitation is the loss of sensitivity of the test in certain groups, such as immunosuppressed patients and young children (2). It should also be remembered that a negative TST obtained early after the onset of infection with *M. tuberculosis* does not exclude infection because the test takes up to eight weeks to emerge as positive. This interval is usually referred to as the "window period."

In the last decade, *in vitro* immunodiagnostic tests have been developed to overcome the deficiencies of the TST. Based on the *in vitro* quantification of the cellular immune response, IGRAs detect interferon-gamma (IFN- γ) release by sensitized T cells after stimulation with

specific *M. tuberculosis* antigens (3). The two main antigens used are the 6-kD *M. tuberculosis* early-secreted antigenic target protein (ESAT-6) and the 10-kD culture filtrate protein (CFP-10), encoded in the region of difference 1 (RD1), which is present in *M. tuberculosis* but not in BCG nor in most NTM (4). Currently there are two commercially available assays: the QuantiFERON®-TB Gold assay (QFT-G) (Qiagen, Hilden, Germany) and the T-SPOT®.TB assay (Oxford Immunotec, Oxford, UK). The QFT-G tests are whole-blood assays that use enzyme-linked immunosorbent assays to detect IFN- γ produced in supernatants by stimulated T cells. The QFT-G in-tube version (QFT-GIT) includes a third antigen, TB7.7, which is encoded in RD11 and is missing from BCG strains and most of the common environmental mycobacteria (5). The T-SPOT.TB detects the number of IFN- γ -producing T cells after stimulation of a definite number of isolated peripheral blood mononuclear cells with ESAT-6 and CFP-10, separately, using an enzyme-linked immunospot assay. Both tests include a positive control that detects the capacity of T cells to produce IFN- γ upon stimulation with a mitogen. Like the TST, IGRAs have a window period of conversion after exposure to *M. tuberculosis*, but the duration of this window has not been clearly determined.

SCOPE AND OBJECTIVES

Currently there is no consensus on the use of IGRAs in different clinical scenarios and settings. Despite the abundance of literature about IGRAs, there is a scarcity of good quality evidence evaluating important patient outcomes in given populations. This, in turn, is reflected in the inconsistency of the recommendations of official organizations and scientific societies, which largely rely on expert opinion (6,7). Moreover, recommendations that are suitable for one area or country may not be appropriate for another. To this end, two

consensus documents were produced in 2008 and 2010 on the diagnosis and treatment of TB in adults (8) and children (9) respectively, where some brief references are included about the use of IGRAs in Spain. Therefore, there was a need for updated recommendations, based on the best available evidence and formulated according to the modern methodology for the elaboration of guidelines.

The current document provides evidence-based guidance to the specialist and primary health-care providers and public health authorities on the use of IGRAs for diagnosing TB infection in both immunocompetent and immunosuppressed adults and children of any age at risk for or suspected of having active TB. The final objective of the document is to minimize the uncertainty and variability in the diagnosis of TB infection by the IGRAs. It is beyond the scope of these guidelines to give advice on when the screening of TB infection should be performed or when and how they should be treated. The authors refer the readers to other guidelines that provided specific guidance on that (10). Nonetheless, the authors stress the need to focus screening on people at risk of developing active TB based on the “Intention to test, intention to treat” principle.

METHODOLOGY

The panel

These guidelines were developed by a panel of experts comprising in infectious diseases, respiratory diseases, microbiology, pediatrics and preventive medicine specialists, together with a methodology expert with experience in the development of clinical guidelines. All panel members were assigned to a specific subgroup (contact tracing, health care workers, children, HIV-infected people, patients with chronic inflammatory diseases, transplant candidates, and patients suspected of having active TB) according to their clinical profile.

Each subgroup was coordinated by one of the three coordinators. The methodologist instructed the members of the panel in the methodology, performed the literature search, guided the deliberations and summarized the recommendations formulated by the panel. All panel members with the exception of the methodologist, participated in the discussions for the formulation of the recommendations. One of the coordinators (M.S.) drafted the manuscript, and finally, all the panel members reviewed and approved the final version. Former TB patients or the public in general were not invited to the panel meetings, since their participation would have required intensive training regarding the implications of test results on health outcomes. Instead, the panel members made inferences about patients' critical and important outcomes considered in the guideline.

Clinical questions

Clinical questions were formulated according to the PICO structure (population, intervention [index test], comparison [reference test] and outcomes), with the outcomes of interest prioritized. No clinical trials had previously evaluated the efficacy of chemoprophylaxis for TB using baseline IGRA results; therefore, the diagnostic yield indexes were derived from observational studies, which constituted indirect evidence of the benefits and consequences of management based on IGRA results. This deficiency limited the quality of the evidence (confidence in the results) in all the questions evaluated. The same limitation was also applicable to the evaluation of IGRAs in the diagnosis of active disease.

Outcomes of interest

Given that the accuracy of the IGRAs for latent TB infection (LTBI) cannot be directly assessed because of the lack of a reference standard, the panel established the following

outcomes, hierarchically classified according to their clinical relevance (from highest to lowest) (11):

1. The efficacy of chemoprophylaxis based on the IGRA results.
2. The predictive values of the IGRAs for the development of active TB based on the IGRA results.
3. The correlation between rate of exposure and risk factors for TB infection.
4. The sensitivity and specificity of IGRAs for the diagnosis of active TB.
5. The concordance between TST and IGRA results.

Whenever available, the panel formulated their recommendations based on the first two outcomes because they best reflected the target populations.

Literature search

Search strategy was designed to identify systematic reviews of diagnostic studies and relevant individual studies that updated existing systematic reviews. Whenever they were available, the panel prioritized clinical trials and prospective observational studies from TB low-prevalence (<25 cases x 100,000) countries which used the commercial tests QTF-GIT and T-SPOT.TB performed in blood with 16-24 h of incubation. When no data from these settings were available, studies from intermediate- or high-prevalence countries were also used. The panel excluded studies of non-commercial IGRAs or studies based on the old version of the QTF-G, as well as studies presenting non-original data, conference abstracts, editorials, reviews, guidelines, and studies conducted in animals. The search was conducted in the following electronic databases, without language or temporal limitations, up to March 2013: MEDLINE (accessed through PubMed) and EMBASE (accessed through Ovid). The panel was kept updated of new literature until June 2015, to ensure the inclusion of relevant

studies published while the guidelines were being developed. Searches comprised a combination of terms that are shown in annex 1. Publications on resource use and costs were identified by searching in the NHS EED database up to October 2014. The panel did not perform a specific literature search about patients' values and preferences because they were not considered clinical outcomes, but it did assess the relative relevance of different outcomes of diagnostic yield.

Data extraction and synthesis of the evidence

Two panel members from each subgroup independently compiled the data using a standardized data extraction sheet. Discrepancies were resolved by discussion and consensus between the two members and the coordinator. The following data were extracted: year of publication, period and country, number of participants, gender, test evaluated, TST results, development of active tuberculosis, and fractions of individuals with true positive, false negative, true negative and false positive results for the calculation of the test's sensitivity and specificity when necessary. The following definitions were used: Sensitivity refers to the proportion of culture-proven tuberculosis patients who had a positive IGRA test; specificity refers to the proportion of symptomatic non-tuberculosis patients who had a negative IGRA test; positive predictive value (PPV) refers to the proportion of patients with a positive IGRA test who had culture-proven tuberculosis, and negative predictive value (NPV) refers to the proportion of symptomatic patients with a negative IGRA test who did not have tuberculosis.

Quality of the evidence

The quality of the evidence was assessed according to the GRADE (*Grading of Recommendations of Assessment Development and Evaluations*) international working group

(12). The panel assessed the quality of the evidence for all outcomes of interest, using the following parameters: study limitations, consistency between the results of the different studies, availability of direct evidence, precision of the estimators of effect, and publication bias. After the evaluation process, the quality of evidence was classified into four categories for each outcome: high, moderate, low, and very low. **Recommendations**

The panel formulated the recommendations with the evidence available for each clinical question according to the GRADE methodology. For the direction (against/for an intervention) and the strength (strong/weak) of a recommendation, the panel weighed the overall quality of the evidence, the balance between benefits and harms, the relative importance of the outcomes, and the resource use and costs. The recommendations were established by consensus between the members of the panel. Methodological material such as data extraction forms, summaries of findings, tables and evidence to recommendation frameworks are available upon request.

RECOMMENDATIONS

A summary of the recommendations is provided in **Table 1**.

Use of IGRAs in contact tracing of patients with TB

Recommendation: *The panel suggests initiating contact tracing with the TST, but in BCG-vaccinated contacts, the positive TST results need to be confirmed with an IGRA performed on the TST reading date. (Weak recommendation; low to very low quality of evidence.)*

1. Summary of the evidence. Five observational studies assessed the predictive values of IGRAs for the development of TB in contacts in low-prevalence countries: four with QTF-GIT (13–16) and one with both the QTF-GIT and T-SPOT.TB (17)). Four studies were prospective (13)(15–17) and one was retrospective (14), and three also assessed the predictive value of

the TST for the development of TB (14)(15)(17). The observational period was variable, but was at least 12 months in each study. The positive predictive value (PPV) for the QTF-GIT (622 subjects) ranged from 0.4% to 17.3%, for the T-SPOT.TB (181 subjects) was 3.3%, and for a TST ≥ 10 mm (795 subjects) ranged from 2.8% to 3.1%. The corresponding negative predictive values (NPV) ranged from 98% to 100% for the QTF-GIT (2426 subjects), was 98.3% for the T-SPOT.TB (118 subjects), and from 99.4% to 100% for a TST ≥ 10 mm (828 subjects) (Table 2).

2. Quality of the evidence. The overall quality of the evidence was *low* to *very low*. The main limiting factors were the lack of direct evidence of the outcomes evaluated and the risk of bias derived from the design of the studies.

3. Justification. The percentage of patients with a negative result who did not develop TB was very high with either type of test (between 98% and 100%). However, because TST is generally more available than IGRAs, it can be used as the basis of screening. In case of a positive result in BCG-vaccinated patients, validation with an IGRA can better select those who require therapy, which should reduce unnecessary treatment. Such reduction, though, seems not to increase the risk of subsequent active disease (18). In BCG-vaccinated populations, the benefits of using IGRAs were considered to surpass the inconveniences, whereas in non-BCG-vaccinated people, the risks and benefits were thought to be more evenly balanced. Therefore, the impact of implementing this strategy will vary with the prevalence of BCG vaccination. Finally, although the lower direct cost would favor the use of TST, a cost-effectiveness study has suggested that the overall costs of including an IGRA in the strategy would be lower after including indirect cost savings from reduced treatment (19).

Use of IGRAs to screen for TB infection in health care workers.

Recommendation: The panel suggests using the TST for initial and periodic screening of health care workers, but the positive TST results need to be confirmed with an IGRA performed on the reading date. (Weak recommendation; moderate and very low quality of evidence for IGRAs and TST respectively.)

If the TST becomes positive and the IGRA remains negative, the panel suggests periodic screening with IGRAs only if there is no suspicion of active disease or evidence of immunosuppression. (Weak recommendation; very low quality of evidence.)

1. Summary of the evidence. Three prospective observational studies assessed the predictive values of IGRAs for the development of TB in health care workers in low-prevalence countries over one to three years; two with QTF-GIT (13)(20) and one with both the QTF-GIT and T-SPOT.TB (21). One of these studies also assessed the predictive value of the TST (21). The three studies were prospective. The PPVs for the development of TB ranged from 0% to 0.4% for QTF-GIT (891 subjects), 0% for T-SPOT.TB (144 subjects from only one study), and 0% for a TST ≥ 10 mm (or 5 mm in immunosuppressed patients) (125 subjects from only one study). The corresponding NPVs were 100% for each of the QTF-GIT (4171 subjects), T-SPOT.TB (2274 subjects), and TST (2293 subjects) (Table 3a). Ten studies assessed the conversion and reversion rates of IGRA (20–29); eight did so with the QTF-GIT (20,22–28) and two with both the QTF-GIT and T-SPOT.T (21,29). One study also assessed the conversions and reversions of the TST (21). All ten studies were observational, but eight were prospective (20–26) and two were retrospective (27)(28). Conversions ranged from 0.7% to 8.3% for QTF-GIT, from 3.9% to 6.1% for T-SPOT.TB, and were 0.9% for the TST. In the only study evaluating both IGRAs and the TST in the same population (21), the

conversion rates were 8.3%, 6.1%, and 0.9% for the QTF-GIT, T-SPOT.TB, and TST ≥ 10 mm (or 5 mm in immunosuppressed patients), respectively. Reversions ranged from 31% to 71% for the QTF-GIT and were 52.9% for the T-SPOT.TB in one study. There were no studies assessing the reversion rates of the TST (**Table 3b**).

2. Quality of the evidence. The overall quality of the evidence was *moderate* for the evaluation of the predictive values of IGRAs, and was *very low* for the TST. The main limiting factors were the lack of direct evidence for the evaluated outcomes and the imprecision caused by the small number of cases.

3. Justification. In cases with a negative result (NPV 100%), both the TST and the IGRAs offer high security against the development of active TB. The extended availability of the TST, together with the high rates of conversions and reversions of IGRAs, justify the use of the TST as the initial test for the screening of health care workers. However, confirming positive TST results with an IGRA will improve the selection of subjects for therapy and should reduce the number of treatments prescribed (18)(30).

Although the lower direct cost would favor the use of TST, the overall costs of including an IGRA in the strategy would be lower after including indirect cost savings derived from reduced treatment, as a cost-effectiveness study has suggested (19). However, the costs of the IGRAs would be excessive against their use in the periodic screening of health care workers.

Use of IGRAs for the diagnosis of active TB in children younger than 5 years

Recommendation: In children younger than 5 years suspected of having active TB, the panel suggests using both the TST and an IGRA to complement the microbiologic and radiographic studies for the diagnosis of active TB. (Weak recommendation; very low quality of evidence.)

1. Summary of the evidence. Only one study has assessed the yield of IGRAs and the TST for the diagnosis of active TB in children under five years of age in low-prevalence countries (31). It was prospective in design and compared IGRAs and the TST head-to-head. For the QTF-GIT (68 subjects), the sensitivity and specificity for diagnosing active TB were 93% (95% CI 77%–99%) and 100% (95% CI 91%–100%), respectively; for the T-SPOT.TB (68 subjects), were 93% (95% CI 77%–99%) and 98% (95% CI 87%–100%), respectively; and for the TST (73 subjects), were 100% (95% CI 88%–100%) and 58% (95% CI 42%–73%), respectively (**Table 8a**).

2. Quality of the evidence. The overall quality of the evidence was *very low*. The main limiting factors were the lack of direct evidence of the outcomes evaluated and the imprecision due to the small number of cases.

3. Justification. Detection of TB infection (by TST or IGRA) as a complementary test for the diagnosis of active disease is important to ensure early treatment in children, where the yields are otherwise poor from smear stains and cultures for mycobacteria. The panel prioritized the need to detect all cases of active TB in children with suspected disease, giving less weight to the potential increase in unnecessary treatment. Since children are particularly vulnerable, the panel deemed that the advantages of the combination of both tests would surpass any associated inconvenience or additional cost. In fact, some members argued for the use of both IGRAs simultaneously, if available.

Use of IGRAs for contact tracing in children

Recommendation: In children older than 5 years, the panel suggests initiating contact tracing with the TST, but in BCG-vaccinated contacts, the positive TST results need to be

confirmed with an IGRA performed on the TST reading date. (Weak recommendation; very low quality of evidence.)

In children younger than 5 years, the panel suggests testing with both the TST and an IGRA, regardless of prior BCG vaccination. (Weak recommendation; low quality of evidence.)

1. Summary of the evidence. Two observational studies assessed the predictive values of the QTF-GIT and the TST for the development of TB in children of high-risk contacts in low-prevalence countries (14)(32). The PPVs for the development of TB were 5.3% and 75% for the QTF-GIT (32 subjects), and were 4% and 14% for the TST (82 subjects). The corresponding NPVs were 100% for both the QTF-GIT (135 subjects) and the TST (84 subjects) (**Table 4**).

2. Quality of the evidence. The overall quality of the evidence was very low. The main limiting factor was the lack of direct evidence of the outcomes evaluated; moreover, the only available study did not provide the number of children younger than 5 years. The results were also imprecise because of the small number of subjects.

3. Justification. The rationale for using two different strategies in children depending on the age threshold of five years was that the sensitivity of IGRAs was considered worse in children under five. In children older than five years, the extended availability of the TST justifies its use as the first-choice test for screening. In BCG-vaccinated subjects with positive TST results, validation with an IGRA will help to better select those who require therapy, which should reduce unnecessary treatments. In children younger than five years, the panel suggests performing the TST and an IGRA because of the importance of maximizing detection of those infected, and that are at high risk of progression to active disease. The

panel deemed that the potential advantages would surpass the inconveniences and additional costs.

Use of IGRAs when screening for TB infection in people infected with HIV

Recommendation. The panel suggests using both the TST and an IGRA to screen for TB infection in people with HIV infection. (Weak recommendation; low quality of evidence.)

In people with HIV and a CD4-cell count <200/mL, the panel suggests using only an IGRA. (Weak recommendation; very low quality of evidence.)

1. Summary of the evidence. Five observational studies have assessed the predictive values of IGRAs for the development of TB in HIV-infected people in low-prevalence countries: two with the QTF-GIT only (33)(34), two with both the QTF-GIT and T-SPOT.TB (35)(36), and one with the T-SPOT.TB only (37). Four studies were prospective (33)(34)(36)(37) and one was retrospective (35). One study also assessed the predictive values of the TST (36). The PPVs for the development of TB ranged from 5.9% to 25% for the QTF-GIT (888 subjects), from 6.3% to 9.1% for the T-SPOT.TB (133 subjects), and was 7.1% for the TST (42 subjects). The corresponding NPVs were 98.8% to 100% for the QTF-GIT (1524 subjects), 98.8% to 100% for the T-SPOT.TB (684 subjects), and 98.9% for the TST (584 subjects) (**Table 5**).

The review identified three systematic reviews that included studies evaluating the use of IGRAs in low-prevalence countries (38–40). The panel selected the newest and most comprehensive review from which to extract sensitivity and specificity data for the detection of active TB and to assess the impact of immunosuppression on the yield of IGRAs in HIV-infected people (39). The sensitivities and specificities were 61% and 72% for the QTF-GIT, and 65% and 70% for the T-SPOT.TB, respectively. In both IGRAs, an increase in the number

of indeterminate results was observed with a CD4 count <200 cells/mL (8.1% for the QTF-GIT and 4% for the T-SPOT.TB).

2. Quality of the evidence. The overall quality of the evidence was *low* to *very low*. The main limiting factors were the lack of direct evidence of the outcomes evaluated, the imprecision due to the small number of subjects, and the risk of bias due to the design of the studies.

3. Justification. The panel prioritized the need to detect all cases of infection, while relativizing the potential increase in unnecessary treatment. Since people infected with HIV are at high risk of progression, the panel deemed that the advantages of using both tests would surpass the inconveniences and additional costs. As justification for screening people with a CD4 count <200 with an IGRA exclusively, the panel considers that the TST rarely identifies infection that has not been detected by IGRAs in patients with advanced immunosuppression.

The implementation of this recommendation is unlikely to be problematic because most HIV-infected patients are treated in specialist hospital units with appropriate laboratory facilities.

Use of IGRAs to screen for TB infection in patients with chronic inflammatory disease before treatment with biologic therapies

Recommendation: The panel suggests using both the TST and an IGRA to screen for TB infection in patients with chronic inflammatory disease before starting biological therapy.

(Weak recommendation; low to very low quality of evidence.)

1. Summary of the evidence. Eight observational studies assessed the predictive values of IGRAs for the development of TB in patients treated with biological therapies in TB low-prevalence countries: four with the QTF-GIT only (41–44), two with both the QTF-GIT and T-

SPOT.TB (36)(45), and two with the T-SPOT.TB only (46)(47). Only two of them assessed the PPV in a small number of patients (36)(47). Seven studies were prospective (36)(41–45)(47) and one was retrospective (46). Seven studies also assessed the predictive values of the TST for the development of TB (36)(41)(42)(44–47). The PPVs for the development of TB were 0% for the QTF-GIT (20 subjects), between 0% and 1.9% for the T-SPOT.TB (131 subjects), and between 0% and 5.4% for the TST (237 subjects). The corresponding NPVs were 97%–100% for the QTF-GIT (2535 subjects), 100% for the T-SPOT.TB (over 563 subjects), and 98.3%–100% for the TST (2468 subjects) (**Table 6**).

Five studies assessed the impact of immunosuppression on the test results (both IGRAs and the TST) (48–52). Four studies, with a total of 747 cases, looked at the prevalence of indeterminate results with the QTF-GIT (48)(49)(51)(52). In all four studies, there was an association between immunosuppression and risk of indeterminate results, while one showed a tight dose–effect correlation with prednisone (48).

2. Quality of the evidence. The overall quality of the evidence was *low* to *very low*. The main limiting factors were the lack of direct evidence of the outcomes evaluated and the risk of bias derived from the design of the studies.

3. Justification. The panel prioritized the need to detect all cases of infection, while relativizing the potential increase in unnecessary treatment. Patients treated with biological therapies are at an increased risk of developing active TB, and when they do, it is frequently as a disseminated or severe; therefore, the panel deemed that the advantages of the combination of both tests would surpass the inconveniences and additional costs. The scarcity of evidence precluded specific recommendations for different patient groups, such as those with rheumatic diseases, psoriasis, and inflammatory bowel disease.

The implementation of this recommendation is unlikely to be problematic because most patients requiring biological therapies are treated in specialist hospital units with appropriate laboratory facilities, and the resources needed to implement IGRA testing are minimal.

Use of IGRAs to screen for TB infection before transplantation

Recommendation: The panel suggests using both the TST and an IGRA to screen for TB infection in patients due to undergo solid organ or allogeneic hematopoietic stem cell transplantation. (Weak recommendation; very low quality of evidence.)

1. Summary of the evidence. Three observational studies assessed the predictive values of IGRAs for the development of TB in patients undergoing solid organ transplantation (SOT) or allogeneic hematopoietic stem cell transplantation (HSCT) in low-prevalence countries (all three studies used the QTF-GIT) (35)(53)(54). In addition, three studies have assessed these predictive values in an intermediate- to high-prevalence country (two with QTF-GIT (55)(56), and only one study was performed using the T-SPOT.TB) (57). One study also assessed the predictive values of the TST for the development of TB (56). Four studies were prospective (53)(55–57) and two were retrospective (35)(54). The PPVs for the development of TB in SOT ranged from 0% to 4% for the QTF-GIT (47 subjects) and were 6% for T-SPOT.TB (71 subjects). The corresponding NPVs were 99%–100% (954 subjects) and 100% (201 subjects). The PPVs in allogeneic HSCT ranged from 0% to 3% for the QTF-GIT (48 subjects) and 0% for the TST (39 subjects). The corresponding NPVs were 95%–100% for the QTF-GIT (265 subjects) and 97.5% for the TST (205 subjects) (**Table 7**).

2. Quality of the evidence. The overall quality of the evidence was very low. The main limiting factors were the lack of direct evidence of the outcomes evaluated and the use of

data from intermediate- to high-incidence settings. Confidence in the results was also limited by short follow-up periods, imprecision, and risk of bias in the studies designs.

3. Justification. The panel prioritized the need to detect all cases of infection, while relativizing the potential increase in unnecessary treatment. Patients with SOT and HSCT who are latently infected are at high risk of developing active TB; therefore, the panel deemed that the advantages of using both tests would surpassed the inconveniences and additional costs. However, although the available evidence allowed only for an overall recommendation for transplants as a whole, the panel decided to focus their recommendation on allogeneic HSCT because the risk of TB in autologous transplant is not clearly higher than that of the general population (58).

The implementation of this recommendation is unlikely to be problematic because most transplant candidates are treated in specialist hospital units with appropriate laboratory facilities, and the resources needed to implement IGRA testing are minimal.

Use of IGRAs for the diagnosis of active TB

Recommendation: The panel recommends against using the IGRAs or TST as a standalone tests for the diagnosis of active TB. (Strong recommendation; low quality of evidence.)

The panel suggests using an IGRA as a proof of TB infection to support the diagnosis in cases with well-founded suspicion of active disease. (Weak recommendation; low quality of evidence.)

1. Summary of the evidence. The review identified five systematic reviews assessing the sensitivity and specificity of IGRAs for detecting active TB (59–63). The panel chose a review that included 20 studies (62), of which eight assessed the QTF-GIT (64–71, 74, 77, 81) (four provided data in non-blood fluids (64–66,69)), and 16 assessed the T-SPOT.TB (64, 66, 72-80,

82-86) (eight provided data for non-blood fluids (64)(66)(72)(73)(76)(80)(83)(84). Twelve studies also assessed the sensitivity and specificity of the TST (67,70–76,82,84–86).

The sensitivities and specificities in the blood were 80% and 79% for the QTF-GIT and 81% and 59% for the T-SPOT.TB, respectively. The corresponding values in non-blood fluids were 48% and 82%, and 88% and 82% for the QTF-GIT, the T-SPOT.TB and the TST respectively. The sensitivity and specificity for the TST were 65% and 75%, respectively (**Tables 8a and b**).

2. Quality of the evidence. The overall quality of the evidence was low. The main limiting factors were the lack of direct evidence of the outcomes evaluated, the use of data from high-incidence settings, and the wide range of patients (adult, child, immunocompetent, and immunosuppressed patients).

3. Justification. Although the quality of evidence was low, it was consistent with regard the sub-optimal performance of all tests when used as standalone tests for the diagnosis of active TB. The dangers of making a diagnosis of TB based exclusively on either TSTs or IGRAs exceed the potential benefits. Nonetheless, the panel considered that a positive test result support the diagnosis of active TB in a patient in whom there was a well-founded suspicion of active disease. A positive test result has been recognized as an independent risk factor for active TB in immunosuppressed patients, and particularly those infected with HIV (60). The panel deemed that the T-SPOT.TB could be considered in particular cases when using non-blood fluids (bronchoalveolar lavage, cerebrospinal, and pleural fluids).

FURTHER CONSIDERATIONS

The panel noted the following additional considerations:

1. The resources needed for IGRAs to be implemented are low. However, implementation in non-urban settings, where a close laboratory for rapid handling of samples is required, may

be difficult. This was acknowledged to be particularly important when using the T-SPOT.TB, which should be performed within the first 24 hours, or in the case of the T-SPOT.TB® Extend, within 48 hours after incubation (87). Furthermore, the need for venous punctures in large collectives and requirement of a reference laboratory to handle sample batches, could make the use of IGRAs difficult for contact tracing at a community level.

2. Although there was no attempt to distinguish between the two IGRAs in the final guidelines, some panel members favored the use of the T-SPOT.TB in HIV-infected (CD4 <200 cells/mL) and children, based on the perception of higher sensitivity over the QTF-GIT. However, it was acknowledged that the available evidence showed no clear difference between the two tests (39) (88).

3. An emphasis was placed on the importance of screening before any underlying disease becomes too advanced, because this can compromise the yield of IGRAs. This was particularly relevant for patients with HIV and for candidates for transplantation or biologic therapies. Likewise, performing the QTF-GIT when leucopenia is present (particularly in HSCT) should be avoided because it increases the likelihood of indeterminate results.

4. There was no specific recommendation on whether the TST and an IGRA should be performed simultaneously or sequentially (start with TST and follow with an IGRA in case of negativity) when both tests are recommended. The panel considers that the choice of strategy should be guided by the circumstances of a given patient and the singularities of each center.

5. Regarding the use of IGRAs in the diagnostic work-up of TB, the panel emphasizes:

- Ensure rational use of IGRAs by using them only when there is a well-founded clinical suspicion.

- A positive IGRA in patients with compatible symptoms, particularly in immunosuppressed patients and children, must prompt active investigation for active TB.
- It remains important to establish a diagnosis of TB by conventional microbiologic and/or molecular methods.

6. If a baseline test is negative (IGRAs or the TST) in HIV-infected patients with very low CD4 cell counts, retesting once immunity has improved with antiretroviral therapy. This approach may be useful to detect additional positive cases.

7. In general, an IGRA is preferred when testing those who are unlikely to return for TST reading, such as patients with alcoholism, drug abuse disorders, and the homeless. In these groups, the use of IGRAs may increase test completion rates.

8. The panel emphasizes the need for health care workers to adhere to TB prevention protocols in place.

APPLICABILITY OF THE GUIDELINES

The panel does not expect major limitations to the applicability of these guidelines in Spain because IGRAs are widely available, particularly the QFT-GIT, and because the cost burden would be easily assumed by the public health system. However, the panel anticipates more difficulty when implementing community contact studies (e.g., in schools, workplaces, and other settings). In such settings, the need for multiple venous punctures and sample collections may be regarded as added inconveniences by public health authorities.

Most recommendations in these guidelines are weak mainly due to the lack of good quality evidence for anticipating and balancing the clinical benefits and disadvantages of TST or IGRA testing. In the case of weak recommendations, clinicians should recognize that

different choices might be appropriate for different patients. Policymaking in this context requires substantial debate and the involvement of many stakeholders, and so health policies are likely to vary between regions.

It is unlikely that in the near future the existing knowledge gaps on the field could be overcome. Not only are there difficulties in conducting appropriate clinical trials but also improvements are expected in the marketed IGRAs, platforms, and latency antigens that will presumably reduce the interest in conducting studies with the current IGRAs. Recently, two prospective longitudinal studies with a large cohort of adults and children have confirmed the poor ability of IGRAs to predict the development of active TB, while confirming their high NPVs; nevertheless, the IGRAs were still shown to be superior to the TST (32)(89). In the meantime, the present evidence-based guidelines try to support decision making for practitioners who use IGRAs in daily clinical practice as well as for stakeholders in public health.

UPDATING OF THE GUIDELINES

The panel considers that these guidelines should be updated within five years of their publication, or earlier if relevant information becomes available.

CONFLICT OF INTEREST STATEMENT

All the authors provided a conflict of interest statement. M.S. declared the following conflicts of interest: he received a fee for speaking at two conferences sponsored by Inverness Medical Iberica, S.A.U., supplier of the QuantiFERON®-TB Gold In-tube in Spain, and he is the PI of a Clinical Trial assessing QuantiFERON®-TB Gold In-tube in contact-tracing, which was supplied with blood collection tubes by Cellestis, Inc. (Carnegie, Australia). Any declared conflicts of interest were not deemed relevant to preclude involvement in the deliberations of the panel.

REFERENCES

1. Testing TT, Infection T. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm reports Morb Mortal Wkly Rep Recomm reports Centers Dis Control. 2000;49(RR-6):1–51.
2. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. *N Engl J Med*. 2004;350(20):2060–7.
3. Santin Cerezales M, Benitez JD. Diagnosis of tuberculosis infection using interferon-gamma-based assays. *Enferm Infecc Microbiol Clin [Internet]*. 2011;29 Suppl 1:26–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21420564>
4. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. *Lancet*. 2000;356:1099–104.
5. Brock I, Weldingh K, Leyten EMS, Sandra M, Ravn P, Andersen P, et al. Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection. 2004;42(6):2379–87.
6. Rutledge TF, Boyd MF, Mazurek M, Jereb J, Vernon A, LoBue P, et al. Updated

- guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm reports Morb Mortal Wkly Rep Recomm reports / Centers Dis Control. 2010;59(RR-5):1–25.
7. Nice. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Nice. 2011;(March).
 8. Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Dominguez JA et al. Diagnóstico y tratamiento de la tuberculosis. Arch Bronconeumol. 2008;44:551–66.
 9. Moreno-Pérez D, Andrés Martín a., Altet Gómez N, Baquero-Artigao F, Escribano Montaner a., Gómez-Pastrana Durán D, et al. Diagnóstico de la tuberculosis en la edad pediátrica. An Pediatría. 2010;72(4):283.e1–283.e14.
 10. Grupo de trabajo de la Guía de Práctica Clínica sobre el Diagnóstico, el Tratamiento y la Prevención de la Tuberculosis. Centro Cochrane Iberoamericano, coordinador. Guía de Práctica Clínica sobre el Diagnóstico, el Tratamiento y la Prevención de la Tuberculosis. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d'Informació, Avaluació i Qualitat en Salut (AIAQS) de Catalunya; 2009. Guías de Práctica Clínica en el SNS: AATRM Nº 2007/26.
 11. World Health Organization. USE OF INTERFERON- γ RELEASE ASSAYS (IGRAs) IN TUBERCULOSIS CONTROL IN LOW- AND MIDDLE-INCOME SETTINGS EXPERT GROUP MEETING REPORT This report contains the collective views of an international group of experts , and does not of a technology does not impl. 2010;(July).
 12. Brozek JL, Aki EA, Alonso-Coello P et al. Grading quality of evidence and strength of recommendations in clinical practice. Allergy. 2009;64:669–77.
 13. Bradshaw L, Davies E, Devine M, Flanagan P, Kelly P, O'Connor K, et al. The role of the interferon gamma release assay in assessing recent tuberculosis transmission in a

- hospital incident. *PLoS One*. 2011;6(6):1–5.
14. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon- γ release assay for developing active tuberculosis: An update. *Am J Respir Crit Care Med*. 2011;183(1):88–95.
 15. Bergot E, Haustraete E, Malbruny B, Magnier R, Salaün MA, Zalcmán G. Observational study of quantiferon[®]-TB gold in-tube assay in tuberculosis contacts in a low incidence area. *PLoS One*. 2012;7(8):3–10.
 16. Haldar P, Thuraisingam H, Patel H, Pereira N, Free R, Entwisle J, et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. 2012;(January 2007):240–6.
 17. Kik S V., Franken WPJ, Mensen M, Cobelens FGJ, Kamphorst M, Arend SM, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. *Eur Respir J*. 2010;35(6):1346–53.
 18. Muñoz L, Santin M. Interferon- γ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: An evidence-based review. *J Infect*. 2013;66(4):381–7.
 19. Nienhaus A, Schablon A, Costa J, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. *BMC Health Serv Res*. BioMed Central Ltd; 2011;11(1):247.
 20. Nienhaus A, Costa JT. Screening for tuberculosis and the use of a borderline zone for the interpretation of the interferon- γ release assay (IGRA) in Portuguese healthcare workers. *J Occup Med Toxicol*. 2013;8(1):1.
 21. Dorman SE, Belknap R, Graviss E a., Reves R, Schluger N, Weinfurter P, et al. Interferon- γ release assays and tuberculin skin testing for diagnosis of latent

- tuberculosis infection in healthcare workers in the united states. *Am J Respir Crit Care Med*. 2014;189(1):77–87.
22. Pollock NR, Campos-neto A, Kashino S. Healthcare Workers With Increased Risk of Latent Tuberculosis. 2013;29(9):878–86.
 23. Zwerling A, Cojocariu M, McIntosh F, Pietrangelo F, Behr M a., Schwartzman K, et al. TB screening in Canadian health care workers using interferon-gamma release assays. *PLoS One*. 2012;7(8).
 24. Ringshausen FC, Nienhaus A, Schablon A, Schlösser S, Schultze-Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. *BMC Infect Dis*. 2010 Jan;10(1):220.
 25. Schablon A, Diel R, Diner G, Anske U, Pankow W, Ringshausen FC, et al. Specificity of a whole blood IGRA in German nursing students. *BMC Infect Dis*. 2011 Jan;11(1):245.
 26. Schablon A, Harling M, Diel R, Nienhaus A. Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicentre prevalence study. *BMC Infect Dis*. 2010;10:107.
 27. Fong KS, Tomford JW, Teixeira L, Fraser TG, Van Duin D, Yen-Lieberman B, et al. Challenges of interferon- γ release assay conversions in serial testing of health-care workers in a TB control program. *Chest*. 2012;142(1):55–62.
 28. Gandra S, Scott WS, Somaraju V, Wang H, Wilton S, Feigenbaum M. Questionable effectiveness of the QuantiFERON-TB Gold Test (Cellestis) as a screening tool in healthcare workers. *Infect Control Hosp Epidemiol*. 2010;31(12):1279–85.
 29. R B. Interferon- γ release assays in the serial testing for latent tuberculosis infection in US healthcare workers [abstract]. *Am J Respir Crit Care Med*. 2010;181:A2263.

30. Casas I, Latorre I, Esteve M, Ruiz-Manzano J, Rodriguez D, Prat C, et al. Evaluation of interferon-gamma release assays in the diagnosis of recent tuberculosis infection in health care workers. *PLoS One*. 2009;4(8).
31. Detjen a K, Keil T, Roll S, Hauer B, Mauch H, Wahn U, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. *Clin Infect Dis*. 2007;45(3):322–8.
32. Altet N, Dominguez J, de Souza-Galvão M-L, Jiménez-Fuentes MÁ, Milà C, Solsona J, et al. Predicting the Development of Tuberculosis with the Tuberculin Skin Test and QuantiFERON Testing. *Ann Am Thorac Soc*. 2015 May;12(5):680-8.
33. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. *Clin Infect Dis*. 2009;48(7):954–62.
34. Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-?? release assay, and the development of active tuberculosis in HIV-seropositive persons. *Diagn Microbiol Infect Dis*. 2011;69(1):59–65.
35. Lange B, Vavra M, Kern W V, Wagner D. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. *Int J Tuberc Lung Dis*. 2012;16(4):492–5.
36. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. *Am J Respir Crit Care Med*. 2014;190(10):1168–76.
37. Clark S a., Martin SL, Pozniak a., Steel a., Ward B, Dunning J, et al. Tuberculosis

antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.

Clin Exp Immunol. 2007;150(2):238–44.

38. Chen J, Zhang R, Wang J, Liu L, Zheng Y, Shen Y, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: A systematic review and meta-analysis. PLoS One. 2011;6(10).
39. Santin M, Muñoz L, Rigau D. Interferon- γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and meta-analysis. PLoS ONE. 2012.
40. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–8.
41. Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, et al. Interferon- γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol. 2011;30(12):1535–41.
42. Garcovich S, Ruggeri a., D'Agostino M, Ardito F, De Simone C, Delogu G, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: A prospective, observational study. J Eur Acad Dermatology Venereol. 2012;26(12):1572–6.
43. Greveson K, Goodhand J, Capocci S, Woodward S, Murray C, Cropley I, et al. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF α therapy. J Crohn's Colitis. European Crohn's and Colitis Organisation; 2013;7(5):412–8.

44. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon- γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. *Arthritis Rheum.* 2012;64(7):2068–77.
45. Mariette X, Baron G, Tubach F, Liote F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. *Ann Rheum Dis.* 2012;71(11):1783–90.
46. Laffitte E, Janssens JP, Roux-Lombard P, Thielen a M, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. *Br J Dermatol.* 2009;161(4):797–800.
47. Jung YJ, Lyu J, Yoo B, Lee CK, Kim YG, Yang SK, et al. Combined use of a TST and the T-SPOT((R)).TB assay for latent tuberculosis infection diagnosis before anti-TNF-alpha treatment. *Int J Tuberc Lung Dis.* 2012;16(January):1300–6.
48. B elard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. *Inflamm Bowel Dis.* 2011;17(11):2340–9.
49. Casas S, Andreu A, Juanola X, Bordas X, Alcaide F, Moure R, et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon- γ release assay in patients considered for anti-tumor necrosis factor- α therapy. *Diagn Microbiol Infect Dis.* Elsevier Inc.; 2011;71(1):57–65.
50. Kleinert S, Tony H-P, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for

- latent tuberculosis infection: performance of tuberculin skin test and interferon-release assays under real-life conditions. *Ann Rheum Dis*. 2012;71(11):1791–5.
51. I. S, F. M, R. S, G. V, C. P, N. S, et al. Evaluation of QuantiFERON(registered trademark)-TB gold in-tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. *Int J Tuberc Lung Dis*. 2010;14(7):834–40.
 52. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. *Am J Gastroenterol*. 2008;103(11):2799–806.
 53. Muñoz L, Gomila A, Casas S, Castellote J, Arnan M, Rafecas A, et al. Immunodiagnostic Tests' Predictive Values for Progression to Tuberculosis in Transplant Recipients. *Transplant Direct*. 2015;1.
 54. Theodoropoulos N, Lanternier F, Rassiwala J, Mcnatt G, Preczewski L, Demayo E, et al. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: A single-center retrospective study. *Transpl Infect Dis*. 2012;14(1):1–8.
 55. Jeong JC, Koo TY, Jeon HJ, Park HC, Ryu HJ, Lee JP, et al. Utility of QuantiFERON-TB Assay for Prediction of Tuberculosis Development in Kidney Transplant Patients in an Intermediate-Tuberculosis-Burden Country: Lack of Evidence for Enhanced Prediction for Short-Term Tuberculosis Development. *Transplant Proc* [Internet]. 2014;46(2):583–7. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0041134513013225>
 56. Moon SM, Lee SO, Choi SH, Kim YS, Woo JH, Yoon DH, et al. Comparison of the

- QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. *Transpl Infect Dis.* 2013;15(1):104–9.
57. Kim S-H, Lee S-O, Park JB, Park I, Park SJ, Yun S-C, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. *Am J Transplant.* 2011;11(9):1927–35.
 58. Cámara R, Martino R. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. ...*Transplantation.* 2000;(62):291–8.
 59. Pai M, Zwerling A, Menzies D. *Annals of Internal Medicine Review Systematic Review : T-Cell – based Assays for the Diagnosis of Latent Tuberculosis Infection : An Update.* 2008;
 60. Diel R, Løddenkemper R, Nienhaus A. Evidence-Based comparison of commercial Interferon-gamma Release assays for detecting active TB a metaanalysis. *Chest.* 2010;137(4):952–68.
 61. Zhou Q, Chen YQ, Qin SM, Tao XN, Xin JB, Shi HZ. Diagnostic accuracy of T-cell interferon- γ release assays in tuberculous pleurisy: A meta-analysis. *Respirology.* 2011;16(3):473–80.
 62. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon- γ release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis. *Eur Respir J.* 2011;37(1):100–11.
 63. Dai Y, Feng Y, Xu R, Xu W, Lu W, Wang J. Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis. *Eur J Clin Microbiol Infect Dis.* 2012;31(11):3127–37.
 64. Dheda K, van Zyl-Smit RN, Meldau R, Meldau S, Symons G, Khalfey H, et al.

- Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. *Thorax*. 2009;64(10):847–53.
65. Baba K, Sørnes S, Hoosen A a, Lekabe JM, Mpe MJ, Langeland N, et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. *BMC Infect Dis*. 2008;8:35.
 66. Dheda K, Van Zyl-Smit RN, Sechi L a., Badri M, Meldau R, Meldau S, et al. Utility of quantitative T-cell responses versus unstimulated interferon- γ for the diagnosis of pleural tuberculosis. *Eur Respir J*. 2009;34(5):1118–26.
 67. Goletti D, Stefania C, Butera O, Amicosante M, Ernst M, Sauzullo I, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: A multicenter TBNET-study. *PLoS One*. 2008;3(10).
 68. Eum S, Lee YJ, Kwak HK, Min J, Via LE, Iii CEB, et al. Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to *Mycobacterium tuberculosis* in Bacille Calmette-Guerin (BCG)-vaccinated individuals. *Diagn Microbiol Infect Dis*. 2008;61(2):181–6.
 69. Chegou NN, Walzl G, Bolliger CT, Diacon AH van den HM. Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis. *Respiration*. 2008;76(2):131–8.
 70. Bianchi L, Galli L, Moriondo M, Veneruso G, Becciolini L, Azzari C, Chiappini E de MM. Interferon-gamma release assay improves the diagnosis of tuberculosis in children. *Pediatr Infect Dis J*. 2009;28(6):510–4.
 71. Bartu V, Havelkova M KE. QuantiFERON-TB Gold in the diagnosis of active tuberculosis. *J Int Med Res*. 2008;36(3):434–7.
 72. Jafari C, Ernst M, Kalsdorf B, Greinert U, Diel R, Kirsten D, et al. Rapid diagnosis of

- smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. *Am J Respir Crit Care Med.* 2006;174(9):1048–54.
73. Losi M, Bossink a., Codecasa L, Jafari C, Ernst M, Thijsen S, et al. Use of a T-cell interferon- γ release assay for the diagnosis of tuberculous pleurisy. *Eur Respir J.* 2007;30(6):1173–9.
74. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al. Clinical evaluation for diagnosing active TB disease and transitional change of two commercial blood tests. *Scand J Infect Dis.* 2008;40(8):629–34.
75. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. *Eur J Clin Microbiol Infect Dis.* 2005;24(8):529–36.
76. Jafari C, Ernst M, Strassburg a., Greinert U, Kalsdorf B, Kirsten D, et al. Local immunodiagnosis of pulmonary tuberculosis by enzyme-linked immunospot. *Eur Respir J.* 2008;31(2):261–5.
77. Goletti D, Carrara S, Vincenti D, Saltini C, Busi Rizzi E, Schininà V, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: A pilot study. *Clin Microbiol Infect.* 2006;12(6):544–50.
78. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Quantitative scoring of an interferon- γ assay for differentiating active from latent tuberculosis. *Eur Respir J.* 2007;30(4):722–7.
79. Kim HJ, Yoon HI, Park KU, Lee CT, Lee JH. The impact of previous tuberculosis history on T-SPOT.TB?? interferon-gamma release assay results. *Int J Tuberc Lung Dis.* 2011;15(4):510–6.
80. Kim S-H, Chu K, Choi S-J, Song K-H, Kim H-B, Kim N-J, et al. Diagnosis of central

- nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. *Clin Vaccine Immunol.* 2008;15(9):1356–62.
81. Kim YK, Uh Y, Lee NS, Cho MY, Eom M, Kim HY. Whole-blood interferon-gamma release assay for diagnosis of tuberculous lymphadenitis. *Tohoku J Exp Med.* 2011;224(3):189–93.
 82. Nicol MP, Davies MA, Wood K, Hatherill M, Workman L, Hawkridge A, Eley B, Wilkinson KA, Wilkinson RJ, Hanekom WA, Beatty D HG. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. *Pediatrics.* 2009;123(1):38–43.
 83. Lee LN, Chou CH, Wang JY, Hsu HL, Tsai TH, Jan IS, Hsueh PR YP. Enzyme-linked immunospot assay for interferon-gamma in the diagnosis of tuberculous pleurisy. *Clin Microbiol Infect.* 2009;15(2):173–9.
 84. Kim SH, Cho OH, Park SJ, Ye BD, Sung H, Kim MN, Lee SO, Choi SH, Woo JH KY. Diagnosis of abdominal tuberculosis by T-cell-based assays on peripheral blood and peritoneal fluid mononuclear cells. *J Infect.* 2009;59(6):409–15.
 85. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD CK. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. *Arch Intern Med.* 2007;167(20):2255–9.
 86. Kim SH, Song KH, Choi SJ, Kim HB, Kim NJ, Oh MD CK. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised patients. *Am J Med.* 2009;122(2):189–95.
 87. Lenders LM, Meldau R, van Zyl-Smit RN, Woodburne V, Maredza A, Cashmore TJ, et al. Comparison of same day versus delayed enumeration of TB-specific T cell responses. *J Infect.* 2010 May;60(5):344–50.
 88. Sollai S, Galli L, de Martino M, Chiappini E. Systematic review and meta-analysis on

the utility of Interferon-gamma release assays for the diagnosis of *Mycobacterium tuberculosis* infection in children: a 2013 update. *BMC Infect Dis*. BioMed Central Ltd; 2014;14 Suppl 1(Suppl 1):S6.

89. Zellweger J-P, Sotgiu G, Block M, Dore S, Altet N, Blunski R, et al. Risk Assessment of Tuberculosis in Contacts by Interferon- γ Release Assays (IGRAs). A TBNET Study. *Am J Respir Crit Care Med*. 2015 May 15;191(10):1176-84.

Table 1. Summary of the recommendations for different clinical settings

	Recommendation	Strength	Quality
IGRAs in contact tracing of patients with TB	The panel suggests initiating contact tracing with the TST, but in BCG-vaccinated contacts, the positive TST results need to be confirmed with an IGRA performed on the TST reading date.	Weak	Low to Very low
IGRAs in health care workers	The panel suggests using the TST for initial and periodic screening of health care workers, but the positive TST results need to be confirmed with an IGRA performed on the reading date. If the TST becomes positive and the IGRA remains negative, the panel suggests periodic screening with the IGRA only if there is no suspicion of active disease or evidence of immunosuppression.	Weak	Moderate (IGRAs) Very low (TST)
IGRAs for the diagnosis of active TB in children younger than 5 years	In children younger than 5 years suspected of having active TB, the panel suggests using both the TST and an IGRA to complement the microbiologic and radiographic studies for the diagnosis of active TB.	Weak	Very low

IGRAs in contact tracing in children	In children older than 5 years, the panel suggests initiating contact tracing with the TST, but in BCG-vaccinated contacts, the positive TST results need to be confirmed with an IGRA performed on the TST reading date.	Weak	Very low
	In children younger than 5 years, the panel suggests testing with both the TST and an IGRA, regardless of prior BCG vaccination.		
IGRAs in people infected with HIV	<p>The panel suggests using both the TST and an IGRA to screen for TB infection in people with HIV infection.</p> <p>In people with HIV and a CD4-cell count <200/mL, the panel suggests using only an IGRA.</p>	Weak	Low to Very low
IGRAs in patients with chronic inflammatory diseases (before starting biologic therapies)	The panel suggests using both the TST and an IGRA to screen for TB infection in patients with chronic inflammatory disease before starting biological therapy.	Weak	Low to Very low
IGRAs for patients requiring transplant (SOT and Allogeneic	The panel suggests using both the TST and an IGRA to screen for TB infection in patients due to undergo solid organ or	Weak	Very low

HSCT)	allogeneic hematopoietic stem cell transplantation.		
IGRAs for active TB	The panel recommends against using neither the IGRAs nor the TST as a standalone test for the diagnosis of active TB.	Strong	Low
	The panel suggests using an IGRA as a proof of TB infection to support the diagnosis in cases with well-founded suspicion of active disease.	Weak	Very low

TB, Tuberculosis; TST, Tuberculin skin test; BCG, Bacille Calmette-Guerin; IGRAs, Interferon-gamma release assays; HIV, Human immunodeficiency virus; SOT, Solid organ transplantation; HSCT, Hematopoietic stem cell transplantation.

Table 2. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in contact tracing of tuberculosis

	Studies (Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	PNV	
QTF-GIT	5 ⁽¹²⁻¹⁶⁾	Observational 4 prospective 1 Retrospective	2 U. Kingdom 1 France 1 Germany 1 Netherland	2 and 3 years 2.9 y. (mean) 3.8 y. (mean) 1.8 y. (median)	0.4%–17.3%	98%–100%	Low to Very low
T- SPOT.TB	1 ⁽¹⁶⁾	Observational Prospective	Netherland	1.8 y. (median)	3.3%	98.3%	Very low
TST (≥10 mm)	3 ^(13, 14, 16)	Observational 2 Prospective 1 Retrospective	1 France 1 Germany 1 Netherland	2.9 y. (mean) 3.8 y. (mean) 1.8 y. (median)	2.8%–3.1%	99.4%–100%	Very low

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube assay

Table 3a. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in health care workers (development of tuberculosis)

	Studies (Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	NPV	
QTF-GIT	3 ^(12, 19, 20)	Observational Prospective	1 U. Kingdom 1 Portugal 1 USA	2 years 1.1 y. (mean) 1.5 years	0%–0.4%	100%	Moderate
T-SPOT.TB	1 ⁽²⁰⁾	Observational Prospective	1 USA	1.5 years	0	100%	Moderate to low
TST (≥10 mm)	1 ⁽²⁰⁾	Observational Prospective	1 USA	1.5 years	0	100%	Very low

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube assay

Table 3b. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in health care workers (conversions and reversions)

	Studies ^(Refs.)	Design	Countries	Results		Quality
				Conversions	Reversions	
QTF-GIT	10 ⁽²⁰⁻²⁹⁾	Observational 8 Prospective 2 Retrospective	5 USA 3 Germany 1 Portugal 1 Canada	0.7%–8.3%	31%–71.4%	Low to very low
T-SPOT.TB	2 ^(20, 29)	Observational 1 Prospective 1 Retrospective	1 Portugal 1 USA	3.9%–6.1%	52.9%	Low to very low
TST (≥10 mm)	1 ⁽²¹⁾	Observational Prospective	1 USA	0.9%	--	Very low

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QTF-GIT, QuantiFERON®-TB Gold in-tube assay

Table 4. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in contact tracing of tuberculosis in children

	Studies (Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	NPV	
QTF-GIT	2 ^(14, 32)	Observational	1 Germany	3.8 years (mean)	5.3%–75%	100%	Very low
TST		2 Prospective	1 Spain		4%–14%	100%	

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QTF-GIT, QuantiFERON®-TB Gold in-tube assay

Table 5. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in people infected with HIV

	Studies (Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	NPV	
QTF-GIT	4 ⁽³³⁻³⁶⁾	Observational 3 prospective 1 Retrospective	Austria 1 Germany 1 Spain 1 Europe (11 countries) 1	1.6 y. (mean) 2.9 y. (mean) 1.9 y. (media) 1.8 y. (mean)	5.9%–25%	98.8%–100%	Low to very low
T-SPOT.TB	3 ⁽³⁵⁻³⁷⁾	Observational 2 Prospective 1 Retrospective	Germany 1 U. Kingdom 1 Europe (11 countries) 1	2.9 y. (media) 1 y. (pos.)/3 m. (neg.) 1.8 y. (median)	6.3–9.1%	98.8%–100%	Low to very low

TST (≥ 10 mm)	1 ⁽³⁶⁾	Observational 1 Prospective	Europe (11 countries) 1	1.8 y. (median)	7.1%	98.9%	Very low
---------------------	-------------------	--------------------------------	-------------------------	-----------------	------	-------	----------

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube assay

Table 6. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in patients with chronic inflammatory diseases, prior to treatment with biologic therapies

	Studies ^(Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	NPV	
QTF-GIT	6 ^(36, 41–47)	Observational Prospective	R. Korea 1 Italy 1 U. Kingdom 1 France 1 Europe (11 countries) 1 Multinational 1	1.5 y. (median) 1 year 2 y. (median) 1 year 1.8 y. (median) 1 year	0 (1 study)	97%– 100%	Low to very low
T-SPOT.TB	4 ^(36, 45–47)	Observational 3 Prospective 1 Retrospective	France 1 Switzerland 1 USA 1 Europe (11 Countries) 1	1 year 1.4 y. (median) 3.1 y. (median) 1.8 y. (median)	0%–1.9%	100%	Low to very low
TST	7 ^(36,41, 42, 44–47)	Observational	R. Korea 1	1.5 y. (median)	0%–5.4%	98.3%–	Low to

		6 Prospective	Italia 1	1 year		100%	very low
		1 Retrospective	U. Kingdom 1	2 y. (median)			
			France 1	1 year			
			Switzerland 1	1.4 y. (median)			
			USA 1	3.1 y. (median)			
			Europe (11 countries) 1	1.8 y. (median)			
			Multinational 1	1 year			

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube assay

Table 7. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in patients prior undergoing solid organ or allogeneic hematopoietic stem cell transplant

	Studies (Refs.)	Design	Countries	Follow-up	Results		Quality
					PPV	NPV	
Solid organ transplantation							
QTF-GIT	4 ^(35, 53-55)	Observational 2 Prospective 2 Retrospective	Spain 1 Germany 1 USA 1 R. Korea 1	4 y. (median) 2.9 y. (mean) 10.8 months (mean) 8.4 months (median)	0%–4%	99%– 100%	Very low
T- SPOT.TB	1 ⁽⁵⁷⁾	Observational Prospective	R. Korea 1	1.9 y. (median)	6%	100%	Very low
Allogeneic hematopoietic stem cell transplantation							
QTF-GIT	3 ^(35, 53, 56)	Observational 2 Prospective 1 Retrospective	Spain 1 Germany 1 R. Korea 1	4 y. (median) 2.9 y. (mean)	0%–3%	95%– 100%	Very low

TST	1 ⁽⁵⁶⁾	Observational Prospective	R. Korea 1	9.6 months (median)	0	97.5%	Very low
-----	-------------------	------------------------------	------------	---------------------	---	-------	----------

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube version assay

Table 8a. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in blood in the diagnosis of active tuberculosis in adults and children under 5 years of age

	Studies ^(Refs.)	Design	Countries	Results		Quality
				Sensibility (95% CI)	Specificity (95% CI)	
Adults						
QTF-GIT	8 ^(65, 67, 68, 70, 71, 74, 77, 81)	Cross-sectional Prospective	Italia 3 R. Korea 2 Czech R. 1 Japón 1 S. Africa 1	80% (75–84)	79% (75–82)	Low
T-SPOT.TB	14 ^(67, 72-78, 80, 82-86)	Cross-sectional Prospective	R. Korea 4 Germany 3 Italia 2 Europe (Italy, Germany)	81% (78–84)	59% (56–62)	

			1 S. Africa 1 Japan 1 Switzerland 1			
TST	12 (67, 70, 76, 82, 84-86)	Cross-sectional Prospective	Germany 3 R. Korea 3 Italy 2 Japan 1 S. Africa 1 Czech R. 1 Europe (Italy, Germany, Netherlands) 1	65% (61-68)	75% (72-78)	
Children younger than 5 years of age						
QTF-GIT	1 (31)	Observational Prospective	Germany	93% (77-99)	100% (91-100)	Very low

T-SPOT.TB				93%	98%	
				(77-99)	(87-100)	
TST (≥ 10 mm)				100%	58%	
				(88-100)	(42-73)	

TST, Tuberculin skin test; IGRAs, Interferon-gamma release assays; QFT-GIT, QuantiFERON®-TB Gold in-tube assay

Table 8b. Synthesis and quality of the evidence used for the recommendation on the use of IGRAs in non-blood fluids in the diagnosis of active tuberculosis in adults

	Studies ^(Refs.)	Design	Countries	Results		Quality
				Sensibility (95% CI)	Specificity (95% CI)	
QTF-GIT	4 ^(64, 65, 66, 69)	Cross-sectional Prospective	S. Africa 4	48% (35–58)	82% (70–91)	Low
T-SPOT.TB	8 ^(64, 66, 72, 73, 76, 80, 83, 84)	Cross-sectional Prospective	S. Africa 2 Germany 2 R. Korea 2 Europe (Italy, Germany) 1 Taiwan 1	88% (82–92)	82% (78–86)	

IGRAs, Interferon-gamma release assays; QTF-GIT, QuantiFERON®-TB Gold In-tube assay

